GSK Acquires RAPT Therapeutics for $2.2 Billion to Develop New Food Allergy Treatment
GSK purchases RAPT Therapeutics for $2.2B, gaining ozureprubart - a promising food allergy treatment requiring injections every 12 weeks instead of every 2 weeks.
/ 14 items
#GSK↓
GSK and Ionis Announce Major Win Against Hepatitis B in Landmark Trials
GSK and Ionis announce breakthrough results for bepirovirsen, a potential first-in-class treatment offering functional cure for chronic hepatitis B in just six months.
Trump Administration Secures Drug Price Cuts from Nine Major Pharmaceutical Companies
Nine pharmaceutical giants including Merck and GSK agree to slash U.S. drug prices to match other wealthy nations under new Trump administration deals, offering discounts up to 70%.
Spero Therapeutics Secures $25M Milestone Payment from GSK Partnership
Spero Therapeutics announces $25 million milestone payment following GSK's FDA resubmission for tebipenem HBr antibiotic treatment for urinary tract infections.
GSK and AnaptysBio Enter Legal Battle Over Cancer Drug Jemperli
GSK subsidiary Tesaro and AnaptysBio file dueling lawsuits in Delaware court over alleged breaches of their 2014 Jemperli licensing agreement, with trial set for July 2026.
AnaptysBio ends UC trial, advances RA program, plans 2026 split
Rosnilimab UC trial discontinued after failing efficacy endpoint. AnaptysBio advances RA program & ANB033 (CeD). Plans firm for 2026 corporate split.